Archiv
Archiv anzeigen:
bis


Quality of Life Associated with Treatments for Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Hoffman KE et al. JAMA 2020 Jan 14

Favorable-risk patients undergoing prostatectomy had worse sexual function at 3 years and worse urinary incontinence at 5 years than those managed with active surveillance.


Recurrent Low-Grade Dysplasia in Patients with Inflammatory Bowel Disease

Sunanda V. Kane, MD, MSPH reviewing de Jong ME et al. Gastrointest Endosc 2020 Jan 7

Recurrent low-grade dysplasia at first follow-up colonoscopy is a risk factor for advanced neoplasia in IBD patients.


Radioactive Biliary Stents for Unresectable Malignant Obstructive Jaundice

Douglas G. Adler, MD, FACG, AGAF, FASGE reviewing Pan T et al. Scand J Gastroenterol 2020 Jan 6

Stents with radioactive iodine seeds improved survival and stent patency.


Luspatercept for Lower-Risk Myelodysplasia with Ring Sideroblasts

Brady L. Stein, MD, MHS reviewing Fenaux P et al. N Engl J Med 2019 Jan 9

Luspatercept resulted in transfusion independence in a significant percentage of MDS patients previously treated with erythropoietin stimulating agents.


Sniffing Out Colorectal Neoplasms

Charles J. Kahi, MD, MS reviewing van Keulen KE et al. Aliment Pharmacol Ther 2019 Dec 20


What Is the Optimal Stent Strategy for Malignant Hilar Biliary Obstruction?

Douglas G. Adler, MD, FACG, AGAF, FASGE reviewing Xia M-X et al. Gastrointest Endosc 2019 Dec 24

Clinical success was greater with bilateral metal stents than with unilateral metal stents or bilateral or unilateral plastic stents.


Long-Term Effects of Repeat Hepatectomy vs. Percutaneous Radiofrequency Ablation for Hepatocellular Cancer

David H. Ilson, MD, PhD reviewing Xia Y et al. JAMA Oncol 2019 Nov 27

Overall survival was not significantly different with repeat hepatectomy than with RFA.


Gene Therapy for Patients with Hemophilia A

Brady L. Stein, MD, MHS reviewing Pasi KJ et al. N Engl J Med 2020 Jan 2

Sustained clinical benefit and safety were observed following administration of adeno-associated virus–mediated factor VIII therapy.


New, Unconfirmed Bone Lesions in Prostate Cancer Patients Receiving Enzalutamide

Robert Dreicer, MD, MS, MACP, FASCO reviewing Armstrong AJ et al. JAMA Oncol 2019 Dec 12, Swami U et al. JAMA Oncol 2019 Dec 12

New lesions on posttreatment scans may represent pseudoprogression and should not necessarily trigger discontinuation of enzalutamide in docetaxel-naive men with metastatic disease.


Archiv
Seite von 87
Editorial Member Board Empfehlungen

Dr. med. Richard Herrmann

Prof. em. für Onkologie Universitätsspital Basel

E-Mail: E-Mail anzeigen

Liebe Kolleginnen und Kollegen!

Die Zahl der veröffentlichten Studien, die für die Betreuung unserer Tumorpatienten von Bedeutung sind, ist kaum mehr überschaubar. Hier hilft uns die Selektion des Teams von Journal Watch. Mit dieser neuen Serie soll eine weitere Auswahl getroffen werden. Diese ist, wie wohl auch die vorgenannte, nicht ohne Subjektivität. Für die Auswahl wichtig war mir ganz besonders die Praxisrelevanz.

Kommentar weiterlesen

Do CDK4/6 Inhibitors Improve Overall Survival in Advanced Breast Cancer?

William J. Gradishar, MD reviewing Turner NC et al. N Engl J Med 2018 Oct 20

Overall survival trended longer with the addition of palbociclib to endocrine therapy in patients with ER-positive/HER2-negative metastatic disease.


Immunotherapy for Breast Cancer Has Arrived

William J. Gradishar, MD reviewing Schmid P et al. N Engl J Med 2018 Oct 20

Adding atezolizumab to nab-paclitaxel prolonged progression-free survival in patients with metastatic triple-negative breast cancer.


Brigatinib for ALK-Positive, Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Camidge DR et al. N Engl J Med 2018 Sep 25

Progression-free survival was prolonged with front-line brigatinib versus crizotinib.


Front-Line Therapy for Extensive-Stage, Small Cell Lung Cancer: A New Standard

Anne S. Tsao, MD reviewing Horn L et al. N Engl J Med 2018 Sep 25

Adding atezolizumab to chemotherapy significantly improved overall and progression-free survival.


A New Standard of Care for Squamous Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Paz-Ares L et al. N Engl J Med 2018 Sep 25

Adding the PD-1 inhibitor pembrolizumab to carboplatin-taxane chemotherapy significantly improved response and survival.


Durvalumab After Chemoradiation for Advanced Non–Small-Cell Lung Cancer

Anne S. Tsao, MD reviewing Antonia SJ et al. N Engl J Med 2018 Sep 25

Two-year overall survival was significantly improved with durvalumab versus placebo.


Omission of Axillary Dissection for Minimal Node-Positive Breast Cancer

William J. Gradishar, MD reviewing Galimberti V et al. Lancet Oncol 2018 Sep 5

Long-term follow-up data confirm that axillary dissection is unnecessary in patients with minimal tumor burden in the sentinel nodes.


Olaparib plus Abiraterone for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Clarke N et al. Lancet Oncol 2018 Jul

Progression-free survival was significantly longer with olaparib than with placebo.


Combination Immunotherapy for Metastatic Melanoma with Brain Metastases

Sunandana Chandra, MD, MS reviewing Tawbi HA et al. N Engl J Med 2018 Aug 23, Turajlic S and Larkin J. N Engl J Med 2018 Aug 23

Ipilimumab plus nivolumab proved safe and efficacious in a phase II trial.


First-Line Lenvatinib vs. Sorafenib for Unresectable Hepatocellular Carcinoma

David H. Ilson, MD, PhD reviewing Kudo M et al. Lancet 2018 Feb 9, Reig M and Bruix J. Lancet 2018 Feb 9

Overall survival was noninferior and progression-free survival and response were superior with lenvatinib.